A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

BMJ Open

Volumn 3, Issue 3, 2013, Pages

  Gross, Jorge Luiz ^a   Rogers, James ^b   Polhamus, Daniel ^b   Gillespie, William ^b   Friedrich, Christian ^c   Gong, Yan ^c   Monz, Brigitta Ursula ^c   Patel, Sanjay ^a,d   Staab, Alexander ^c   Retlich, Silke ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Metrum Research Group   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LINAGLIPTIN; SITAGLIPTIN;

AGE; ARTICLE; BAYESIAN LEARNING; DOSE RESPONSE; DRUG EFFICACY; EMBASE; ETHNICITY; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84877643773     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001844     Document Type: Article

References (59)

1. Higgins JPT, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org (accessed 11 Oct 2011).
2. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv.
3. Ahn JE, French JL. Longitudinal aggregate data model-based meta-analysis with NONMEM: Approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 2010;37:179-201.
4. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58.
5. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9.
6. Ito K, Ahadieh S, Corrigan B, et al. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Demen 2010;6:39-53.
7. Rogers JA, Polhamus D, Gillespie WR, et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: A beta regression meta-analysis. J Pharmacokinet Pharmacodyn 2012;39:479-98.
8. Demin I, Hamren B, Luttringer O, et al. Longitudinal model-based meta-analysis in rheumatoid arthritis: An application toward model-based drug development. Clin Pharmacol Ther 2012;92:352-9.
9. Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005;7:E513-22.
10. Luu KT, Raber SR, Nickens DJ, et al. A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Clin Pharmacol Ther 2010;87:421-5.
11. Renard D, Looby M, Kramer B, et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res 2011;12:54.
12. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain-results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 2005;25:715-25. (Pubitemid 41208313)
13. Mandema JW, Boyd RA, DiCarlo LA. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: A dose-response meta-analysis. Clin Pharmacol Ther 2011;90:820-7.
14. Mandema JW, Salinger DH, Baumgartner SW, et al. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 2011;90:828-35.
15. Gibbs JP, Fredrickson J, Barbee T, et al. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: Meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol 2011;52:1494-505.
16. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008(2):CD006739.
17. Merck & Co. Inc. US Food and Drug Administration Drug Approval Package. Januvia (sitagliptin phosphate) tablets. 2006. http://www. accessdata.fda.gov/drugsatfda-docs/nda/2006/021995s000TOC.cfm (accessed 11 Oct 2011).
18. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2011;13:258-67.
19. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010;27:1409-19.
20. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study(1). Diabet Med 2011;28:1352-61.
21. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74.
22. Gallwitz B, Uhlig-Laske B, Bhattacharaya S, et al. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with T2DM inadequately controlled on metformin. Abstract 39-LB. Paper presented at: American Diabetes Association 71st Scientific Sessions; 24-28 June 2011; San Diego, CA, USA.
23. Patel S, Barnett A, Harper R, et al. 1 yr Linagliptin monotherapy is well tolerated & sustains improvement in glycaemic control in patients for whom metformin is inappropriate. Abstract D-0920. Paper presented at: IDF World Diabetes Congress 4-8 December, 2011; Dubai, UAE.
24. Rafeiro E, Ross S, Meinicke T, et al. Efficacy and safety of 5 mg daily dosing regimens with linagliptin in patients with type 2 diabetes inadequately controlled on metformin. Paper presented at: 47th Annual Meeting of the European Association for the Study of Diabetes; 12-16 September, 2011; Lisbon, Portugal.
25. Hornick K. The R FAQ. 2011. http://CRAN.R-project.org/doc/FAQ/R-FAQ.html (accessed 23 Jan 2012).
26. Gelman A, li Meng X, Stern H. Posterior predictive assessment of model fitness via realized discrepancies. Statistica Sinica 1995;6:733-807. (Pubitemid 126706389)
27. Gastonguay MR. A full model estimation approach for covariate effects: Inference based on clinical importance and estimation precision. AAPS J 2004;6(S1):Abstract W4354.
28. Gastonguay MR. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies. Abstract 2229. Paper presented at: Annual Meeting of the Population Approach Group in Europe; 7-10 June 2011; Athens, Greece.
29. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled onmetformin: A 2-year study. Int J Clin Pract 2010;64:562-76.
30. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7. (Pubitemid 44912190)
31. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431-9.
32. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43. (Pubitemid 44912191)
33. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87. (Pubitemid 47219404)
34. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-39. (Pubitemid 46998442)
35. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45. (Pubitemid 47261855)
36. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383-94.
37. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-16.
38. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-8.
39. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71.
40. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68. (Pubitemid 44841980)
41. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80.
42. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69.
43. Boehringer Ingelheim. Boehringer Ingelheim Study 1218.05. A Randomized, Double-blind, Placebo-controlled, Five Parallel Group Study Investigating the Efficacy and Safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg Administered Orally Once Daily) Over 12 Weeks in Drug Naive and Treated Patients With Type 2 Diabetes With Insufficient Glycemic Control (Study Includes an Open-label Metformin Treatment Arm). 2011. http://clinicaltrials.gov/ct2/show/NCT00328172? term=1218.5&rank=1 (accessed 11 Jan 2012).
44. Araki E, Kawamori R, Inagaki N, et al. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Paper presented at: IDF World Diabetes Congress; 4-8 December 2011; Dubai, UAE.
45. Lewin AL, Liu D, Patel S, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Diabetologia 2010;53(Suppl 1):S326.
46. United States Deprtment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. 2008. http://www.fda.gov/downloads/Drugs//Guidances/ucm071624.pdf (accessed 29 Nov 2012).
47. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 06/WC500129256.pdf (accessed 29 Nov 2012).
48. Mould DR. Model-based meta-analysis: An important tool for making quantitative decisions during drug development. Clin Pharmacol Ther 2010;92:283-6.
49. Mandema JW, Gibbs M, Boyd RA, et al. Model-based meta-analysis for comparative efficacy and safety: Application in drug development and beyond. Clin Pharmacol Ther 2011;90:766-9.
50. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-61.
51. Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med 2009;121:40-5.
52. Eckhardt M, Hauel N, Himmelsbach F, et al. 3,5-Dihydro-imidazo [4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors. Bioorg Med Chem Lett 2008;18:3158-62. (Pubitemid 351718346)
53. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13:594-603.
54. Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials. Diabetes Metab Res Rev 2011;27:362-72.
55. Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35.
56. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35:533-8. (Pubitemid 46513255)
57. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78.
58. Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8.
59. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab 2011;13:939-46.